SR123781A: A New Once-Daily Synthetic Oligosaccharide Anticoagulant for Thromboprophylaxis After Total Hip Replacement SurgeryThe DRIVE (Dose Ranging Study in Elective Total Hip Replacement Surgery) Study
Michael R. Lassen, MD*,*,
Ola Dahl, MD, PhD ,
Patrick Mismetti, MD ,
Dirk Zielske, MD and
Alexander G.G. Turpie, MD, FACC||
* Hørsholm Hospital, Hørsholm, Denmark
Thrombosis Research Institute, London, England
University Hospital of Saint-Étienne, Saint-Étienne, France
sanofi-aventis, Frankfurt am Main, Germany
|| McMaster University, Hamilton, Ontario, Canada.
View larger version (16K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 Dose-Response Curves for SR123781A
Incidence of confirmed adjudicated venous thromboembolism (VTE) (blue) from surgery up to 10 days post-surgery or day of mandatory venography (whichever came first), and incidence of confirmed adjudicated major bleeding (red) from first study drug injection up to last study drug injection plus 3 days. Point estimates for SR123781A groups (dots) and enoxaparin group (circles), and logistic regression curve (solid lines) with 2-sided 95% confidence intervals (dotted lines).
|
|
|
